Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way

Executive Summary

Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling in this population.

Advertisement

Related Content

Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits
Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline
Clovis Transitions To Commercial Stage On Rubraca Approval
Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy
FDA defies advisers; OK's AZ's ovarian cancer drug Lynparza

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel